Psychedelic therapy seems to be a promising tool for the management of mental health conditions including depression,[1][2][3][4] anxiety,[3][4] and substance use disorders[5][6][7] (primarily alcohol and tobacco use disorders). Currently, the strongest evidence exists for depression and anxiety, including difficult-to-treat conditions like treatment-resistant depression (when two different antidepressants have failed to work) and depression/anxiety related to major illnesses (e.g., terminal cancer).[1] Even in people with no apparent mental or physical diseases, psychedelic therapy has demonstrated long-term (>1 year) improvements in well-being.[8][9] The vast majority of research has been done using psilocybin, although ayahuasca and LSD have also been studied with seemingly comparable efficacy.[4]
A major benefit of psychedelic therapy is the minimal dosing required to achieve a therapeutic effect. Unlike antidepressants, which need to be dosed daily and can take upwards of 4 weeks to begin to work, a single psychedelic session has been found to improve depression and anxiety symptoms rapidly (in some studies within 1 day), with effects potentially lasting 6 months or longer.[10] While positive effects have been consistently shown after a single session, there is some evidence to suggest that two psychedelic sessions produces better results.[4]
References
- ^Ko K, Kopra EI, Cleare AJ, Rucker JJPsychedelic therapy for depressive symptoms: A systematic review and meta-analysis.J Affect Disord.(2023-Feb-01)
- ^Nan-Xi Li, Yi-Ru Hu, Wang-Ni Chen, Bin ZhangDose effect of psilocybin on primary and secondary depression: a preliminary systematic review and meta-analysisJ Affect Disord.(2021 Sep 17)
- ^Simon B Goldberg, Brian T Pace, Christopher R Nicholas, Charles L Raison, Paul R HutsonThe experimental effects of psilocybin on symptoms of anxiety and depression: A meta-analysisPsychiatry Res.(2020 Feb)
- ^Robert F Leger, Ellen M UnterwaldAssessing the effects of methodological differences on outcomes in the use of psychedelics in the treatment of anxiety and depressive disorders: A systematic review and meta-analysisJ Psychopharmacol.(2021 Sep 14)
- ^van der Meer PB, Fuentes JJ, Kaptein AA, Schoones JW, de Waal MM, Goudriaan AE, Kramers K, Schellekens A, Somers M, Bossong MG, Batalla ATherapeutic effect of psilocybin in addiction: A systematic review.Front Psychiatry.(2023)
- ^Bogenschutz MP, Ross S, Bhatt S, Baron T, Forcehimes AA, Laska E, Mennenga SE, O'Donnell K, Owens LT, Podrebarac S, Rotrosen J, Tonigan JS, Worth LPercentage of Heavy Drinking Days Following Psilocybin-Assisted Psychotherapy vs Placebo in the Treatment of Adult Patients With Alcohol Use Disorder: A Randomized Clinical Trial.JAMA Psychiatry.(2022-Oct-01)
- ^Krebs TS, Johansen PØLysergic acid diethylamide (LSD) for alcoholism: meta-analysis of randomized controlled trials.J Psychopharmacol.(2012-Jul)
- ^Aday JS, Mitzkovitz CM, Bloesch EK, Davoli CC, Davis AKLong-term effects of psychedelic drugs: A systematic review.Neurosci Biobehav Rev.(2020-Jun)
- ^Goldberg SB, Shechet B, Nicholas CR, Ng CW, Deole G, Chen Z, Raison CLPost-acute psychological effects of classical serotonergic psychedelics: a systematic review and meta-analysis.Psychol Med.(2020-Dec)
- ^Bruno Romeo, Laurent Karila, Catherine Martelli, Amine BenyaminaEfficacy of psychedelic treatments on depressive symptoms: A meta-analysisJ Psychopharmacol.(2020 Oct)